Lamei Pharmaceuticals: Wholly-owned subsidiary receives approval notice for chemical raw drug listing application

Lamei Pharmaceuticals announces that its wholly-owned subsidiary, Chongqing Lamei Longyu Pharmaceutical Co., Ltd., has received the "Approval Notice for the Marketing Application of Triptorelin Acetate" issued by the National Medical Products Administration.
Triptorelin acetate, as the acetate salt form of triptorelin, has its conventional injection and sustained-release formulations approved for marketing in the European Union.
The original patented formulation of this product, Triptorelin Acetate Injection (brand name: Decapeptyl), produced by Swiss company Ferring Pharmaceuticals, has been approved for import.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned